TCR2 Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast

Loading...
Loading...
  • Earnings to be released after market close on Monday, May 13, 2019

CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (TCR2) TCRR, a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will release results for the first quarter 2019 and provide a corporate update on Monday, May 13, 2019, after the market closes.

TCR2 will webcast its first quarter 2019 earnings conference call on Monday, May 13, 2019, beginning at 5:00 PM ET. The live audio webcast can be accessed by clicking on the Events link in the "Investors" section of www.tcr2.com. A replay of the call will also be archived on the website and will be available until the company's next quarterly earnings call. 

About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T™ cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarincoma. For more information about TCR2, please visit www.tcr2.com.

Media:
Kathy Vincent
(310) 403-8951
kathy@kathyvincent.com 

Investors:
Ian Somaiya
Chief Financial Officer
(617) 949-5210
ian.somaiya@tcr2.com  

Loading...
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...